泰格醫藥(300347.SZ)：2022年度扣非淨利潤同比增長25.01% 擬10派5.5元
格隆匯3月28日丨泰格醫藥(300347.SZ)披露2022年年度報吿，報吿期內，公司實現營業收入70.85億元，同比增長35.91%；歸屬於上市公司股東的淨利潤20.07億元，同比下降30.19%；歸屬於上市公司股東的扣除非經常性損益的淨利潤15.40億元，同比增長25.01%；基本每股收益2.32元，擬向全體股東每10股派發現金紅利5.5元(含税)。
報吿期內，公司克服各種不利影響，實現了業務增長。新增合同金額96.73億元，與上年同期新增合同金額基本持平，2022年新增訂單主要來自制藥公司、生物科技公司和醫療器械公司持續加大研發投入、在中國開展臨牀試驗項目的吸引力日益增強以及中國公司向海外市場進一步擴大研發活動。
隨着監管制度的日趨嚴格、新技術和分析工具的迅速普及和全球化趨勢加速等因素影響，客户對公司的新興服務，如科學事務、早期藥理學、藥物警戒、真實世界研究等業務需求增加。截至報吿期末，公司累計待執行合同金額137.86億元，同比增長20.88%。
在團隊的努力和所有合作伙伴的支持下，公司繼續保持在國內臨牀CRO行業的市場領先地位。自2004年至報吿期末為中國65%的1類新藥獲批提供了專業服務。2022年度，公司佔中國遺傳辦(中國人類遺傳資源管理辦公室，HGRAC)國際合作審批、備案項目的佔比為13.6%。該報吿期助力4個新冠疫苗產品成功獲得中國及海外的緊急使用授權。
截至報吿期末，公司有680個正在進行的藥物臨牀研究項目，上年同期為567個。截至報吿期末，公司員工人數為9233人，覆蓋全球50個國家，其中海外員工1426名。其中，有1100餘名專業臨牀監查員(CRA)，2400餘名專業臨牀研究協調員(CRC)，有超過800名的數據管理及統計分析人員，以及1400餘名實驗室服務人員。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
